Intestinal NK/T-cell lymphoma
Conditions
Interventions
Observation group:None
Sponsors
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age = 18 years; 2.Patients who underwent colonoscopy or surgery during outpatient or inpatient visits at Renji Hospital affiliated with Shanghai Jiao Tong University School of Medicine between May 2020 and May 2025, and were pathologically diagnosed with intestinal NK/T-cell lymphoma. The diagnosis of intestinal NK/T-cell lymphoma is based on the criteria proposed by Dawson et al. [1]: (1) No enlargement of superficial lymph nodes at initial diagnosis, or enlargement but pathological examination does not confirm malignant lymphoma; (2) Normal white blood cell count and classification; (3) No mediastinal lymph node enlargement on chest imaging; (4) No enlargement of liver or spleen. The pathological diagnosis of extranodal NK/T-cell lymphoma is based on the 5th edition of the WHO classification of lymphoid and hematopoietic tumors [2]: (1) Extensive ulceration and tumor cell infiltration at the primary mucosal site, irregular nuclear morphology of tumor cells, frequent mitotic figures, presence of apoptotic bodies, and scant or clear cytoplasm; (2) Expression of cytotoxic markers such as TIA-1, granzyme B, and perforin; (3) Positive for EBER (Epstein-Barr virus-encoded small RNA); (4) Expression of NK or T-cell phenotypes, such as CD56+, CD2+, sCD3+; (5) Site of occurrence is outside lymph nodes; 3.Patients have preserved tissue and/or blood samples available for research, with storage conditions meeting the requirements for multi-omics testing; complete clinical data, including basic demographic information, diagnostic and treatment records, providing a foundation for data analysis; 4.Patients have signed informed consent forms during the treatment process, allowing the use of their past samples and clinical data for scientific research;
Exclusion criteria
Exclusion criteria: 1.Age < 18 years; 2.Coexisting other malignant tumors, affecting the accuracy of characteristic analysis of this disease; 3.Incomplete clinical or pathological information, unable to meet the analysis requirements; 4.The preserved samples cannot meet the testing requirements due to quality or storage issues (e.g., insufficient tissue quantity, improper storage, etc.);
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proteomics data;Accuracy;Sensitivity; | — |
Countries
China
Contacts
Public ContactZhao Shuliang
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
Outcome results
None listed